Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Tumor cell-based vaccine contributes to local tumor irradiation by eliciting a tumor model-dependent systemic immune response
Avtorji:ID Remic, Tinkara (Avtor)
ID Serša, Gregor (Avtor)
ID Levpušček, Kristina (Avtor)
ID Lampreht Tratar, Urša (Avtor)
ID Uršič Valentinuzzi, Katja (Avtor)
ID Cör, Andrej (Avtor)
ID Kamenšek, Urška (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://www.frontiersin.org/articles/10.3389/fimmu.2022.974912/full
 
.pdf PDF - Predstavitvena datoteka, prenos (9,70 MB)
MD5: 80F557B3BB354B0E881DBA5E65758073
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:Multimodal treatment approaches, such as radio-immunotherapy, necessitate regimen optimization and the investigation of the interactions of different modalities. The aim of this study was two-fold. Firstly, to select the most effective combination of irradiation and the previously developed tumor cell-based vaccine and then to provide insight into the immune response to the selected combinatorial treatment. The study was performed in immunologically different murine tumor models: B16F10 melanoma and CT26 colorectal carcinoma. The most effective combinatorial treatment was selected by comparing three different IR regimens and three different vaccination regimens. We determined the local immune response by investigating immune cell infiltration at the vaccination site and in tumors. Lastly, we determined the systemic immune response by investigating the amount of tumor-specific effector lymphocytes in draining lymph nodes. The selected most effective combinatorial treatment was 5× 5 Gy in combination with concomitant single-dose vaccination (B16F10) or with concomitant multi-dose vaccination (CT26). The combinatorial treatment successfully elicited a local immune response at the vaccination site and in tumors in both tumor models. It also resulted in the highest amount of tumor-specific effector lymphocytes in draining lymph nodes in the B16F10, but not in the CT26 tumor-bearing mice. However, the amount of tumor-specific effector lymphocytes was intrinsically higher in the CT26 than in the B16F10 tumor model. Upon the selection of the most effective combinatorial treatment, we demonstrated that the vaccine elicits an immune response and contributes to the antitumor efficacy of tumor irradiation. However, this interaction is multi-faceted and appears to be dependent on the tumor immunogenicity.
Ključne besede:experimental oncology, multimodal treatment, radio-imunotherapy
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:05.09.2022
Založnik:MDPI AG
Leto izida:2022
Št. strani:str. 1-12
Številčenje:Vol. 13
PID:20.500.12556/DiRROS-15470 Novo okno
UDK:602.6/.7
ISSN pri članku:1664-3224
DOI:10.3389/fimmu.2022.974912 Novo okno
COBISS.SI-ID:120231939 Novo okno
Avtorske pravice:by Authors
Opomba:Nasl. z nasl. zaslona; Opis vira z dne 5. 9. 2022;
Datum objave v DiRROS:14.09.2022
Število ogledov:935
Število prenosov:522
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Frontiers in immunology
Skrajšan naslov:Front. immunol.
Založnik:Frontiers Research Foundation
ISSN:1664-3224
COBISS.SI-ID:30774233 Novo okno

Gradivo je financirano iz projekta

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P3-0003-2022
Naslov:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:14.09.2022

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:eksperimentalna onkologija, multimodalno zdravljenje, radio-imunoterapija


Nazaj